Promising results from the GLORIA study presented at the ASCO 2022 meeting





Image source: Reuters

(Boursier.com) – Noxxon Pharma NV, a biotechnology company specializing in developing improved cancer therapies that target the tumor microenvironment (MET), presents key data from the GLORIA Phase 1/2 study in brain cancer (glioblastoma) evaluating NOX A12 as a poster at the American Society for Clinical Medicine Annual Meeting for Oncology (ASCO) to be held in Chicago, Illinois, USA, June 3-7.

Le poster intitulé “Radiotherapy and bigolololapsid (NOX-A12) in unmethylated MGMT glioblastoma partially resected or biopsied only: provisional data from the German multicenter phase 1/2 GLORIA trial” from présenté par le Dr Frank A. Giordano .

This poster highlights the following:
90% of patients who received NOX-A12 with radiotherapy achieved a reduction in tumor volume, compared to 25% of patients in a control group receiving standard care.
40% of patients who received NOX-A12 with radiotherapy had a partial response (defined as a reduction in tumor volume of more than 50%) compared to 10% in a control group receiving standard care.
In 30% of patients who received NOX-A12 in combination with radiotherapy, one or more non-target lesions (small secondary lesions) completely disappeared.
Tumor infiltration by activated cytotoxic T cells and M1 macrophages was observed in the two patients who underwent re-operative surgery during NOX-A12 treatment.
The combination of radiotherapy and NOX-A12 was safe and well tolerated, with no dose-specific toxicity and no treatment-related mortality. Only 4% of grade 2 or higher adverse events were considered to be related only to NOX-A12.

“We are pleased with these promising results, which demonstrate the potential of our flagship product NOX-A12 in brain cancer and confirm our innovative approach to targeting the tumor microenvironment. We will continue to report data from part of the study. Study escalation and we eagerly await interim results from the ongoing expanded study exploring combination therapies. It is a very difficult disease to treat and these results bring us closer to our goal of providing better treatment options and hopefully restoring patients,” said Aram Manjasrian, CEO of Noxxon.

See also  Convertible Bonds Financing Program with a maximum nominal total amount of EGP 81 million

A copy of the presentation in poster form, as well as a synthetic video, will be available on the NOXXON website. More information about the GLORIA study (NCT04121455) is available at ClinicalTrials.gov.

After the ASCO 2022 conference, NOXXON will host a webinar featuring Dr. Giordano, who will comment on the ASCO poster presentation and discuss the results of the Phase 1/2 study in more detail. GLORIA, June 10 at 2pm CEST (8am EST).


© 2022 Boursier.com


LEAVE A REPLY

Please enter your comment!
Please enter your name here